INTRODUCTION
Zika virus (ZIKV) infection in humans typically causes mild and nonspecific clinical symptoms, but in pregnant women, it results in devastating fetal consequences, including microcephaly, intrauterine growth retardation, and other congenital malformations (Brasil et al., 2016a; Honein et al., 2017; Johansson et al., 2016; Mlakar et al., 2016; Rasmussen et al., 2016) . ZIKV has also been associated with Guillain-Barré syndrome as well as other neurologic disorders in adults (Brasil et al., 2016b; Dos Santos et al., 2016; Parra et al., 2016; Soares et al., 2016) . ZIKV infection typically results in approximately 1 week of viremia, but prolonged viremia has been observed in infected pregnant women and in semen from infected men (Brasil et al., 2016b; Calvet et al., 2016; Driggers et al., 2016) . ZIKV has also been reported in fetal brain and placental tissue (Bhatnagar et al., 2017) . These data suggest that the virus may persist in anatomic sanctuaries following clearance of virus in the periphery, although the extent of virus persistence following ZIKV infection remains unknown.
ZIKV infection of rhesus and cynomolgus monkeys has been shown to recapitulate many key clinical findings, including rapid control of acute viremia, early invasion of the central nervous system, and prolonged viral shedding and fetal pathology in pregnant female animals Adams Waldorf et al., 2016; Dudley et al., 2016; Osuna et al., 2016) . Studies in mice have similarly demonstrated robust viral replication and fetal pathology in pregnant female animals, infection of the central nervous system, and invasion of the male reproductive system (Cugola et al., 2016; Govero et al., 2016; Larocca et al., 2016; Miner et al., 2016) .
Innate immune control of ZIKV has been suggested by the fact that mice lacking type 1 interferon (IFN) activity exhibited substantially enhanced viral pathology (Lazear et al., 2016) , and IFN-stimulated genes (ISGs) have been shown to restrict viral replication in vitro (Savidis et al., 2016) . Adaptive immune control of ZIKV has been demonstrated by the capacity of virus-specific neutralizing antibodies to prevent and control infection in adoptive transfer studies in mice and monkeys Barouch et al., 2017; Larocca et al., 2016; Sapparapu et al., 2016) . Cross-reactive antibodies with other flaviviruses such as dengue virus (DENV) have also been described, although the potential clinical relevance of these cross-reactive antibodies remains to be determined Charles and Christofferson, 2016; Dejnirattisai et al., 2016; Stettler et al., 2016) .
In this study, we investigate in detail the early virologic, immunologic, and transcriptomic events following ZIKV infection in rhesus monkeys. Acute viremia was rapidly controlled in peripheral blood by day 10 but persisted for up to 42 days in cerebrospinal fluid (CSF) and for up to 72 days in lymph nodes (LN) and colorectal biopsies. ZIKV-specific neutralizing antibodies emerged rapidly by day 7 and correlated with virologic control in peripheral blood. In contrast, virus-specific antibodies were not detected in CSF for the duration of the study. Viral persistence in both CSF and LN also correlated with upregulation of mechanistic target of rapamycin (mTOR), proinflammatory, and antiapoptotic signaling pathways. Taken together, these data suggest a mechanism for viral persistence in these anatomic sites and suggest that persistent or occult ZIKV infection in these compartments may occur more frequently than previously appreciated.
RESULTS

Persistent ZIKV in CSF and LN of Infected Rhesus Monkeys
We previously developed ZIKV challenge stocks from outbreak strains from Brazil (ZIKV-BR; Brazil/ZKV2015) (Cugola et al., 2016) and Puerto Rico (ZIKV-PR; PRVABC59), and both virus stocks demonstrated robust viral replication in mice and rhesus monkeys Larocca et al., 2016) . To evaluate the virologic and immunologic events of acute ZIKV infection, we infected 16 Indian-origin rhesus monkeys (M. mulatta) with 10 6 plaque-forming units (pfu) (10 9 viral particles [vp] ), 10 5 pfu (10 8 vp), 10 4 pfu (10 7 vp), or 10 3 pfu (10 6 vp) of ZIKV-BR and ZIKV-PR by the subcutaneous (s.c.) route (N = 2/group).
We first monitored virus shedding at multiple anatomic sites. Robust viral replication was observed in peripheral blood for 6-10 days, consistent with prior studies of ZIKV infection in monkeys Dudley et al., 2016; Osuna et al., 2016) . Peak plasma viral loads were a mean of 6.01 log RNA copies/ml (range 5.18-6.71 log RNA copies/ml) ( Figure 1A ). Peak viral loads were observed on day 2 at the 10 6 pfu dose, on day 3 at the 10 5 pfu dose, on days 3-4 at the 10 4 pfu dose, and on days 4-5 at the 10 3 pfu dose, suggesting a trend toward delayed and prolonged viral replication with lower doses. Sporadic but lower levels of ZIKV shedding were observed in urine, cervicovaginal secretions, and saliva ( Figures 1A and 1B) , although most animals still had virus detected in lymph nodes on day 14 ( Figure 1C ). Viral loads could not be performed in semen as a result of the limited number of male animals in this study (N = 2) and challenges with sample acquisition in these animals.
In contrast with the rapid clearance of virus in plasma, ZIKV shedding was prolonged in the CSF (Figure 2A ), with 75% (three of four) of animals that received the lowest 10 3 pfu dose still positive in CSF on days 21-42, although CSF viral loads were variable. CSF samples contained few leukocytes (0-8 WBC/ml) and did not have chemistry profiles that indicated frank meningitis ( Figure S1 ). CSF samples also had very few red blood cells (0-6 RBC/ml), confirming that there was no detectable contamination with peripheral blood ( Figure S1 ). Replication-competent virus in CSF from days 21 and 42 was confirmed by viral outgrowth assays ( Figure 2B ).
To assess viral persistence in lymphoid and colorectal tissues in greater detail, we infected four additional rhesus monkeys with 10 3 pfu (10 6 vp) of ZIKV-BR and followed viral loads in plasma, whole blood, lymph node biopsies, and colorectal biopsies. Viral loads in whole blood were only marginally prolonged compared with plasma (Murray et al., 2017) . In contrast, we observed persistent virus in lymph nodes and colorectal tissue for up to 72 days ( Figure 2C ). We confirmed ZIKV in both paracortical regions and germinal centers of lymph nodes from ZIKV-infected (10 9 -10 6 vp) ZIKV-BR or ZIKV-PR (N = 2/group). Viral loads (log 10 ZIKV RNA copies/ml or copies/10 6 cells) are shown in (A) plasma and urine, (B) cervicovaginal secretions and saliva, and (C) lymph node and colorectal biopsies. Viral loads were determined on days 0, 1, 2, 3, 4, 5, 6, 7, 10, and 14 for plasma and urine samples and on days 0, 3, 7, and 14 for the other samples. Data is shown for all eight animals in each panel, except for only seven females in each panel for cervicovaginal secretions. Assay sensitivity is >100 ZIKV copies/ml and >100 ZIKV copies/10 6 cells. monkeys on day 35, but not from a SHIV-infected monkey, by immunohistochemistry ( Figure 2D ). RNA in situ hybridization confirmed rare infected cells, and replication-competent virus was shown by viral outgrowth assays (data not shown). These data demonstrate prolonged ZIKV RNA in CSF, LN, and colorectal tissue from infected rhesus monkeys.
Adaptive Immune Responses
We observed the rapid emergence of ZIKV-specific binding (p = 0.0004) and neutralizing (p < 0.0001) antibodies in serum by week 1 following infection ( Figure 3A ; Figure S2 ). Both binding antibodies by ELISA and neutralizing antibodies by microneutralization (MN50) assays Larocca et al., 2016) were detected. Binding antibody titers correlated with MN50 titers at weeks 1-2 (p < 0.0001, R = 0.72; Figure 3A ). Log MN50 titers of 1.27-3.43 were observed in 87.5% (14 of 16) of (A) Viral loads (log 10 ZIKV RNA copies/ml) in plasma and CSF in the study described in Figure 1 . Figure S1 .
animals at week 1, and log MN50 titers of 3.08-3.86 were detected in 100% (16 of 16) of animals at week 2. Week 1 MN50 titers also correlated inversely with day 6 plasma viral loads ( Figure 3A ; p = 0.019, R = À0.56), suggesting that the emergence of virus-specific neutralizing antibodies was associated with virologic control in plasma.
In contrast with the rapid development of ZIKV-specific antibodies in plasma, no ZIKV-specific IgM or IgG was detected in CSF at any time point through week 24 ( Figure 3B ). In contrast, ZIKV-specific IgG was consistently high in serum through week 24 ( Figure 3B ). These data suggest that ZIKV-specific antibodies produced in the periphery did not detectably cross the blood-CSF barrier. We speculate that the absence of ZIKV-specific antibodies in the CSF may contribute to viral persistence in the central nervous system, and eventual clearance of CSF virus is thus likely dependent on other immune mechanisms.
ZIKV-specific cellular immune responses to prM, Env, Cap, and NS1 were not detected by IFN-g ELISPOT assays at week 1 but were observed in a subset of animals at week 2 and in the majority of animals by week 5 ( Figure 3C ). CD8 + and CD4 + T lymphocyte responses to Env, Cap, and NS1 were also detected by multiparameter intracellular cytokine staining assays by week 2 ( Figure 3D ). However, cellular immune responses did not correlate with virologic control (data not shown), although we cannot exclude the possibility that cellular immune responses against other ZIKV antigens may have played a role. These data suggest that robust ZIKV-specific cellular immune responses expanded largely after peripheral virus had already been controlled.
Early Innate Immune Responses
To characterize the early innate immune responses in ZIKVinfected rhesus monkeys, we assessed transcriptomic profiles in peripheral blood mononuclear cells on days 0, 2, 4, 6, 14, and 21 following ZIKV infection using the Affymetrix Rhesus Gene 1.0 ST Array rheMac2 platform. Multidimensional unsupervised clustering using the full transcriptome of all animals showed principal clustering by time point (p = 0.03; days 0, 2, and 14 versus days 4 and 6), with minimal contribution by ZIKV strain or inoculum dose, which allowed a kinetic analysis of gene expression using the complete group of animals ( Figure S3 ). The number of differentially expressed genes peaked on days 4 and 6 as compared with day 0 (Figure S3 ), which temporally correlated with peak plasma viral loads ( Figure 1A ). We next used gene set enrichment analysis (GSEA) (Subramanian et al., 2005) and compiled lists of gene sets (Liberzon et al., 2015; Nakaya et al., 2011) to identify the pathways upregulated and downregulated following ZIKV infection of rhesus monkeys (Figures 4A and 4B ; Figure S4 ). Robust induction of IFN-a (normalized enrichment scores [NES] = 3.02; false discovery rate [FDR] < 0.0001) and antiviral (NES = 2.28; FDR < 0.0001) pathways were observed on days 2, 4, and 6. IFN-stimulated genes (ISGs) (OAS2, IFT1/2/3, ISG15, IRF7, IFI44, MX1, and MX2) (Schoggins et al., 2011) also peaked on day 6 ( Figure 4C ). In addition, acute ZIKV infection upregulated components of the inflammasome (NOD2, NLRP3, CXCL10, BTG2, BST2, OSM), proinflammatory cytokines and chemokines (TNF-a, IL-1, IL-18, CCR7, CCL2, and CCL20), and immunomodulatory pathways (IL-10, TGF-b, and T regulatory cells) ( Figure 4A ; Figure S4 ), analogous to what we previously observed for acute SIV infection in rhesus monkeys (Barouch et al., 2016) . We also observed increases in mTOR signaling (NES = 1.92; FDR = 0.0014) and T cell exhaustion (NES = 1.96; FDR = 0.0009) pathways following ZIKV infection ( Figure 4A ; Figure S4 ). mTOR signaling orchestrates numerous cell processes in living organisms by regulating homeostasis, protein synthesis, transcription, autophagy, and metabolism (Thoreen, 2017) and also regulates immune function (Powell et al., 2012) and neurologic development (Lipton and Sahin, 2014) . Figure S4 ). Taken together, these data demonstrate that acute ZIKV infection is characterized by robust and rapid upregulation of proinflammatory, interferon, antiviral, and immunomodulatory pathways and downregulation of T cell and B cell signaling pathways ( Figure 4D ).
To confirm these transcriptomic findings, we monitored serum cytokines by Luminex assays in rhesus monkeys following ZIKV infection. Monkeys developed robust early proinflammatory responses as evidenced by substantial increases in serum levels of TNF-a, IL-2, IL-10, and IL-12/IL-23 on days 4-6 following infection (p = 0.0003; p = 0.0019; p = 0.0011; and p = 0.015 comparing day 6 versus day 0 for each cytokine, respectively, Mann-Whitney tests) ( Figure 5A ). These data confirm that ZIKV replication triggered rapid innate immune responses in peripheral blood. In contrast, only minimal cytokine responses were observed in CSF, even in animals that exhibited prolonged ZIKV replication in the central nervous system ( Figure 5B ). Cytokine responses in both serum and CSF were essentially negative on days 21 and 42 (data not shown).
Pathways Correlated with Acute Plasma Viral Loads
To define the transcriptomic pathways that correlate with plasma viral loads following ZIKV infection, we performed a linear regression analysis correlating the full transcriptome to viral loads during acute infection ( Figure 6A ). IFN-a signaling (NES = 1.59; FDR = 0.08) and IFN-g signaling (NES = 1.56; FDR = 0.09), as well as various ISGs (IFI44, ISG15, OAS1, TRIM5, IRF7, MX2, DDX60, and TLR7), correlated positively with acute viral loads on days 2, 4, and 6 ( Figure 6A ; Figure S5 ), suggesting that ZIKV replication rapidly triggered host innate immune responses. NK cell signaling (NES = 2.4; FDR = 0.001), IL-10 signaling (NES = 1.55; FDR = 0.09), and oxidative phosphorylation (NES = 2.03; FDR = 0.0016) pathways also correlated positively with plasma viral loads ( Figure 6A ; Figure S5 ). Moreover, mTOR signaling pathways on day 2, including mTORC1 (NES = 2.2; FDR = 0.001) and PI3K_AKT_mTOR (NES = 1.6; FDR = 0.08), correlated positively with viral loads ( Figure 6A ). In contrast, extracellular matrix (NES = À2.05; FDR = 0.02), epithelial mesenchymal transition (NES = À1.73; FDR = 0.10), myogenesis (NES = 1.83; FDR = 0.06), and signal transduction and plasma membrane pathways (NES = À1.82; FDR = 0.06) correlated negatively with plasma viral loads ( Figure 6A ; Figure S5 ).
A previously reported target-cell-limited model of acute ZIKV replication kinetics (Osuna et al., 2016) , which utilized a different challenge virus and a different inoculum dose, did not optimally describe viral dynamics in the present study. We therefore added to this model the impact of neutralizing antibodies and the effect of the early type 1 interferon response, which greatly improved the model fit (p < 3.0310
À4
). The best fit with biologically plausible parameters was found when type 1 interferon activity was assumed to begin on day 1.5 and when neutralizing antibody activity was assumed to begin on day 6 (negative log likelihood = 105.7; BIC = 247.4) ( Figure S6 ). This model fit the viral dynamics well for all four inoculum doses tested. These findings suggest that both the innate interferon response and the adaptive neutralizing antibody response contributed to virologic control in the periphery.
Pathways Correlated with Persistent CSF and LN Viral Loads
We next evaluated the transcriptomic pathways associated with persistent CSF and LN viral loads using CSF viral loads from days 14 and 21 and LN viral loads from days 3 and 14. Plasma viral loads were negative on day 14 in all animals. Pathways that correlated with persistent CSF and LN viral loads following ZIKV clearance in the periphery included mTOR signaling (NES = 1.92; p = 0.00517), TGF-b (NES = 1.60; p = 0.00669), IFN-a signaling (NES = 2.61; p = 0.003), acute inflammation (NES = 1.60; p = 0.0056), and TNF-a signaling (NES = 1.66; p = 0.0032) (Figures 6B-6D ; Figure S7 ). Genes associated with these pathways correlated significantly with viral loads at both time points tested in CSF and LN, including mTOR, Rictor, CXCL10, OAS2, IFI44, BANK1, NLRP3, IL1b, EIF4G, EIF4E, PIK3CB, and SMAD3 ( Figure 6C ). We speculate that both mTOR signaling and proinflammatory pathways contributed to the survival of ZIKV-infected cells and viral persistence.
In contrast, pathways associated with extracellular matrix (ECM) signaling (NES = À2.00; p = 0.005) and platelet activation (NES = À1.85; p = 0.0047) negatively correlated to viral loads in CSF and LN (Figures 6B-6D ; Figure S7 ). Genes involved in collagen formation and cell adherence, including MLLT4, COL14A, COL5A, COL6A, MMP1, MMP2, MMP3, MMP8, MMP19, SLC22A2, SLC6A13, SLC7A9, and SLC17A1, correlated negatively to viral loads in both CSF and LN ( Figure 6C ). Downregulation of ECM pathways has also been reported for DENV (Afroz et al., 2016) , suggesting a common pathophysiologic pathway. Anti-apoptotic genes (BIK, BCL2A1, BCL2L1) also correlated positively, and pro-apoptotic genes (CASP8, CAV1, CLU, LMNA) correlated negatively to persistent CSF and LN viral loads ( Figure S7 ), suggesting that ZIKV infection creates a milieu that favors survival of infected cells. Taken together, these data suggest that viral persistence in the CSF and LN correlated with upregulation of mTOR, proinflammatory, and anti-apoptotic pathways, which promote survival of infected cells, and downre- gulation of ECM pathways, which may be important for lymphocyte recruitment to sites of infection ( Figures 6D and 7) .
DISCUSSION
In this study, we describe the early events following acute ZIKV infection of rhesus monkeys at a greater level of detail than previously reported. Integrated virologic, immunologic, and transcriptomics data demonstrated a rapid and robust proinflammatory response in the first few days of infection coincident with ZIKV replication, characterized by upregulation of type 1 IFN, antiviral, and immunomodulatory pathways. A rapid ZIKV-specific neutralizing antibody response in peripheral blood was also evident by day 7 and correlated with virologic control in plasma. In contrast with the rapid virologic control in peripheral blood, viral persistence was observed in the CSF for up to 42 days and in LN and colorectal tissues for up to 72 days, suggesting the presence of multiple anatomic sanctuaries for the virus. Persistent virus at these sites correlated with upregulation of mTOR, proinflammatory, and antiapoptotic pathways and downregulation of ECM pathways, suggesting a potential mechanism for viral persistence. These findings raise the possibility that occult or persistent neurologic and lymphoid disease may occur in ZIKV-infected humans more commonly than currently recognized.
mTOR orchestrates numerous cell processes in living organisms by regulating homeostasis, protein synthesis, transcription, autophagy, metabolism, and brain function and development (Thoreen, 2017) . The finding that upregulation of the mTOR signaling pathways correlated with persistent viral loads in both CSF and LN suggests that ZIKV infection may directly stimulate mTOR machinery, which promotes survival of infected cells. Moreover, mTOR signaling has been shown to play a key role in neurodevelopment, including the proliferation of neural stem cells, neuronal circuit development, plasticity, and higher complex functions (Lipton and Sahin, 2014; Switon et al., 2017; Thoreen, 2017) . Overexpression of mTOR during early embryonic development in transgenic mice resulted in cortical atrophy and microcephaly, whereas overexpression of mTOR in adults led to neurodegeneration (Kassai et al., 2014) . Moreover, brain-specific knockouts of Raptor and Rictor, which are key components of mTOR complex 1 and 2, respectively, also led to microcephaly and early postnatal lethality Thomanetz et al., 2013) . These findings suggest that ZIKV-induced stimulation of the mTOR pathway, together with persistent CSF viral loads, may be critical for the development of microcephaly and other neurologic disorders associated with ZIKV infection. Future studies targeting the mTOR pathway are therefore warranted.
Recent reports have also shown inhibition of ECM pathways by both DENV and ZIKV (Afroz et al., 2016; Zhang et al., 2016) , suggesting a common pathophysiologic pathway for these flaviviruses. ECM proteins are widely expressed in the developing and adult nervous system and may also be critical for lymphocyte trafficking (Barros et al., 2011) . These data suggest that viral persistence may result from stimulation of pathways that promote survival of ZIKV-infected cells and that block the recruitment of immune cells to the site of infection (Figures 6 and 7) .
ZIKV-specific antibodies were not detected in CSF, despite robust and prolonged responses in peripheral blood (Figure 3) , suggesting an additional mechanism for viral persistence in immunoprivileged sites. Although we did not evaluate ZIKV-specific antibody levels in lymph nodes in the present study, studies with monoclonal antibodies have shown substantial variation in antibody biodistribution to different tissues, including lymph node and brain, as compared with peripheral blood (D) Gene interaction networks for mTOR, inflammation and interferon, and extracellular matrix pathways that were correlated positively or negatively to CSF and LN viral loads. Red and blue nodes are genes correlated positively and negatively to viral loads. Node size is proportional to the number of interacting neighbors. Edge width depicts the strength of the interaction between each pair of genes. Networks inference was performed using Cytoscape. See also Figures S5, S6 , and S7. (de Boer et al., 2016; Tichauer et al., 2014; Wang et al., 2008) . In the CSF, it is likely that the absence of ZIKV-specific antibodies contributed to viral persistence in that compartment.
Our data confirm and extend prior studies of ZIKV pathogenesis in nonhuman primates Dudley et al., 2016; Osuna et al., 2016) . A recent study identified virus in neuronal, lymphoid, and reproductive tissues through days 28-35 following infection in rhesus monkeys (Hirsch et al., 2017) , and persistent ZIKV infection has also been reported in the testes in mice . Taken together, these findings suggest that ZIKV may persist for prolonged periods in multiple anatomic sanctuaries, including the central nervous system, lymphoid system, gastrointestinal tract, and genitourinary tract.
Our findings demonstrate that early ZIKV replication in rhesus monkeys is partially restricted by early innate interferon responses and is then definitively controlled in peripheral blood by the rapid emergence of virus-specific neutralizing antibodies by day 6-10. In the central nervous system, lymph nodes, and gastrointestinal tissues, however, virus can persist for a substantially longer period of time, likely as a result of activation of mTOR, proinflammatory, and anti-apoptotic pathways that promote survival of infected cells, as well as exclusion of virus-specific antibodies from CSF. If persistent or occult neurologic and lymphoid disease similarly occurs following clearance of peripheral virus in ZIKV-infected humans, such a finding would have important clinical implications. It is likely that mTOR activation and persistent virus in the central nervous system contribute to the hallmark neuropathology of ZIKV infection.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed and will be fulfilled by the Lead Contact (Dan Barouch; dbarouch@bidmc.harvard.edu). 
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Rhesus Monkeys 16 outbred, Indian-origin, healthy young adult male and female rhesus monkeys (Macaca mulatta) were included in the initial study. These monkeys were housed at Bioqual, Rockville, MD. Animals were infected with 10 3 -10 6 pfu (10 6 -10 9 vp) of our ZIKV-BR or ZIKV-PR challenge stocks by the s.c. route (N = 2/group). An additional 4 outbred, Indian-origin, healthy young adult male and female rhesus monkeys were housed at Alphagenesis, Yemassee, SC and infected with 10 3 pfu (10 6 vp) of our ZIKV-BR challenge stocks by the s.c. route (N = 4/group). Animals were tested for baseline flavivirus neutralizing antibodies. None of the monkeys were previously enrolled in other studies. All animal studies were approved by the appropriate Institutional Animal Care and Use Committee (IACUC).
Cell lines
Vero cells (World Health Organization, NICSC-011038011038) were maintained in EMEM media supplemented with 10%FBS, 6mM L-glutamine and 1x pen/strep. Cells were passaged twice a week and incubated at 37 C, 10% CO2.
METHODS DETAILS RT-PCR
RT-PCR assays were utilized to monitor viral loads, essentially as previously described Larocca et al., 2016) . RNA was extracted from plasma or other samples with a QIAcube HT (QIAGEN, Germany) using the Qiacube 96 Cador pathogen HT or the Qiacube 96 RNeasy 96 kit. CSF samples were centrifuged prior to analyses. The wild-type ZIKV BeH815744 Cap gene was utilized as a standard. RNA standards were generated using the AmpliCap-Max T 7 High Yield Message Maker Kit (Cell Script) and purified with RNA clean and concentrator kit (Zymo Research, CA, USA). RNA quality and concentration was assessed by the BIDMC Molecular Core Facility. Log dilutions of the RNA standard were reverse transcribed and included with each RT-PCR assay. Viral loads were calculated as virus particles (VP) per ml or virus particles per 10 6 cells as shown in Figures 1-2 . Assay sensitivity was > 100 copies/ml and > 100 ZIKV copies/10 6 cells.
ELISA
Monkey ZIKV Env ELISA kits (Alpha Diagnostic International, TX, USA) were used to determine endpoint binding antibody titers using a modified protocol . 96-well plates coated with ZIKV Env protein were first equilibrated at room temperature with 300 ml of kit working wash buffer for 5 min. 6 ml of monkey serum was added to the top row, and 3-fold serial dilutions were tested in the remaining rows. Samples were incubated at room temperature for 1 hr, and plates washed 4 times. 100 ml of anti-monkey IgG HRP-conjugate working solution was then added to each well and incubated for 30 min at room temperature. Plates were washed 5 times, developed for 15 min at room temperature with 100 ml of TMB substrate, and stopped by the addition of 100 ml of stop solution. Plates were analyzed at 450nm/550nm on a VersaMax microplate reader using Softmax Pro 6.0 software (Molecular Devices, CA, USA). ELISA endpoint titers were defined as the highest reciprocal serum dilution that yielded an absorbance > 2-fold over background values. Log 10 endpoint titers are reported and shown in Figure 3 .
Virus Neutralization Assay
A high-throughput, standardized ZIKV microneutralization (MN) assay was utilized for measuring ZIKV-specific neutralizing antibodies, essentially as previously described Larocca et al., 2016) . Briefly, serum samples were serially diluted three-fold in 96-well micro-plates, and 100 ml of ZIKV-PR containing 100 PFU were added to 100 ml of each serum dilution and incubated at 35 C for 2 hr. Supernatants were then transferred to microtiter plates containing confluent Vero cell monolayers (World Health Organization, NICSC-011038011038). After incubation for 4 d, cells were fixed with absolute ethanol: methanol for 1 hr at -20 C and washed three times with PBS. The pan-flavivirus monoclonal antibody 6B6-C1 conjugated to HRP (6B6-C1 was a gift from JT Roehrig, CDC) was then added to each well, incubated at 35 C for 2 hr, and washed with PBS. Plates were washed, developed with 3,3 0 ,5,5 0 -tetramethylbenzidine (TMB) for 50 min at room temperature, stopped with 1:25 phosphoric acid, and absorbance was read at 450 nm. For a valid assay, the average absorbance at 450 nm of three non-infected control wells had to be % 0.5, and virus-only control wells had to be R 0.9. Normalized absorbance values were calculated, the MN50 titer was determined by a log mid-point linear regression model. The MN50 titer was calculated as the reciprocal of the serum dilution that neutralized R 50% of ZIKV, and seropositivity was defined as a titer R 10, with the maximum measurable titer 7,290. Log 10 MN50 titers are shown in Figure 3A -B and Figure S2 .
Viral Outgrowth Assay MW6 plates seeded with Vero WHO cells (World Health Organization, NICSC-011038011038) were infected with CSF and plasma from ZIKV infected monkeys. Aliquots of the media were taken daily after infection and subjected to RT-PCR as described above. Viral loads of the cultures are shown in vp/ml in Figure 2B .
ELISPOT assay ZIKV-specific cellular immune responses were assessed by interferon-g ELISPOT assays shown in Figure 3C using pools of overlapping 15-amino-acid peptides covering the prM, Env, Cap, and NS1 proteins (JPT, Berlin, Germany), essentially as we previously described Larocca et al., 2016) . 96-well multiscreen plates (Millipore, MA, USA) were coated overnight with 100 ml/well of 10 mg/ml anti-human interferon-g (BD Biosciences, CA, USA) in endotoxin-free Dulbecco's PBS (D-PBS). The plates were then washed three times with D-PBS containing 0.25% Tween 20 (D-PBS-Tween), blocked for 2 hr with D-PBS containing 5% FBS at 37 C, washed three times with D-PBS-Tween, rinsed with RPMI 1640 containing 10% FBS to remove the Tween 20, and incubated with 2 mg/ml of each peptide and 2 3 10 5 monkey PBMC in triplicate in 100 mL reaction mixture volumes. Following an 18 hr incubation at 37 C, the plates were washed nine times with PBS-Tween and once with distilled water. The plates were then incubated with 2 mg/ml biotinylated anti-human interferon-g (BD Biosciences, CA, USA) for 2 hr at room temperature, washed six times with PBS-Tween, and incubated for 2 hr with a 1:500 dilution of streptavidin-alkaline phosphatase (Southern Biotechnology Associates, AL, USA). Following five washes with PBS-Tween and one with PBS, the plates were developed with nitroblue tetrazolium-5-bromo-4-chloro-3-indolyl-phosphate chromogen (Pierce, IL, USA), stopped by washing with tap water, air-dried, and read using an ELISPOT reader (Cellular Technology Ltd., OH, USA). The numbers of spot-forming cells (SFC) per 10 6 cells were calculated. The medium background levels were typically < 15 SFC per 10 6 cells.
Intracellular Cytokine Staining
12-color intracellular cytokine staining (ICS) assays shown in Figure 3D were performed essentially as described (Barouch et al., 2016) 
Immunohistochemistry
Immunohistochemistry for ZIKV Env, shown in Figure 2D was performed using standard techniques. Briefly, lymph nodes were fixed in 10% neutral buffered formalin for 24-72 hr then transferred to 70% ethanol. Formalin-fixed paraffin embedded (FFPE) tissues were deparaffinized in xylene and rehydrated through graded ethanol solutions to distilled water. Endogenous peroxidase activity was blocked by incubation in 3% H 2 O 2 , and antigen retrieval was accomplished by microwaving sections for 20 min in citrate buffer (Dako). Tissue sections were treated for nonspecific protein binding (Protein Block; Dako) and then sequentially incubated with monoclonal mouse anti-ZIKV Env (Biofront) at 1:200 followed by biotinylated horse anti-mouse IgG (Vector Labs). Antigen-antibody complexes were localized by application of streptavidin-peroxidase conjugate (Dako) followed by development in the chromogenic substrate 3,3-diaminobenzidine (Dako).
Luminex assay
Serum was thawed on ice and neutralized with 0.05% Tween-20 for 15 min at room temperature. Samples were prepared using the Milliplex Nonhuman Primate 23-plex (Millipore) according to manufacturers' protocol and washed and resuspended in 4% formaldehyde in D-PBS for 1 hr on a plate shaker. Samples were then washed and resuspended in Magpix drive fluid for analysis. Data was acquired on a Magpix instrument running xPONENT 4.2 (Luminex). Cytokine cut-off values for analysis were the following: IL-2 (2.4 pg/ml), IL-10 (12.2 pg/ml), TNF-a (2.4 pg/ml serum, 9.8 pg/mL CSF), IL-12/23 (p40) (9.8 pg/ml serum days 4 and 6, 2.4 pg/ml CSF and serum days 0 and 2). Cytokine levels were analyzed using GraphPad Prism v6.03 (GraphPad Software, CA, USA) and are shown in Figure 5 .
Transcriptomics Cells were isolated from peripheral blood at d2, 4, 6, 14 and 21 as well as lymph node at d3 and 14 and stored in RNAlater. Total RNA extraction was performed using the automated RNeasy HT Qiacube kit according to manufacturer's instructions (QIAGEN). Reverse transcription reactions were performed to obtain cDNAs, and proper cDNA amplification was confirmed using Agilent 2100 Bioanalyzer (Agilent Technologies). cDNA was hybridized to Rhesus Genome rheMac2 platform (Affymetrix) at the Microarray Core of the Boston University. Analysis of the genome array output data was conducted using the statistical language R (http://www.r-project.org/) and the Linear Models for Microarray Data (LIMMA) statistical package from Bioconductor (http://bioconductor.org/) (Gentleman et al., 2004) . Quantile normalization, followed by a log 2 transformation using the Bioconductor package LIMMA, was applied to process microarrays. Batch correction was performed to correct for any technical or biological effect using ComBat R (http://bioconductor.org/). The LIMMA package was used to fit a linear model to each probe and to perform a moderated Student's t test on various differences of interest between time points. For data mining and functional analyses, genes that satisfied a p value cut-off of 0.05 were selected. When indicated, p values were corrected for multiple comparisons using Benjamin & Hochberg method (FDR < 5%). The LIMMA package was used to fit a linear regression model to each probe where the log 2 expression of each transcript was used as an independent variable and viral load or neutralizing antibody titers, respectively, as continuous variables. Pearson correlations and a p value cut-off of 0.05 were used to assess significant genes that correlated with virologic and immunologic data.
Pathway enrichment was performed using gene set enrichment analyses GSEA (http://software.broadinstitute.org/gsea/msigdb/ index.jsp) and a list of gene sets including MSigDB Hallmark collection and published immunological modules (Subramanian et al., 2005) . To assess the significance of GSEA results, 1000 permutations were performed. The minimum size of tested gene sets was set to 5 genes and the maximum to 5000. A nominal p value of 0.05 was used to assess the significance of gene sets enrichment. An enrichment score (ES) was calculated to reflect the degree of the over-representation of the top (or bottom) genes in the ranked gene list. GSEA allows for the identification of a core list of genes (leading edge genes) that contribute to the ES from genes within each significantly enriched gene set. The normalized enrichment score and FDR shown in the main text correspond to day 4 following ZIKV infection (Figure 4, Figures S3 and S4 ). Module enrichment map was generated using EnrichmentMap application under Cytoscape (http://cytoscape.org/). Functional annotation and network inference were performed using Cytoscape (http://cytoscape. org/).
To identify mechanisms of persistence of CSF and LN viral loads, a linear regression model using R programming language was used to correlate genes expressed in PBMC on day 14 and 21 to viral load in CSF on day 14 and 21 respectively and to correlate genes expression in LN to viral load in LN on day 3 and 14 (Figure 6, Figures S5 and S7) . Next, we identified genes that correlated to CSF and LN viral loads for each time point separately. To account for genes that correlated positively or negatively with viral loads at different time points, we measured the Fisher combined p value for each gene correlated to CSF viral loads on day 14 or 21 and gene correlated to LN viral loads on day 3 and day 14, where the Fisher combined p value, P is defined as:
where P representing the combined p value, k the number of time points and ln(P i ) is the natural log of each specific time points' p value.
Viral Dynamics Modeling
A mathematical model was used to investigate the within-host ZIKV dynamics in plasma as shown in Figure S6 . The model was a standard target cell limited model that included a viral eclipse phase and (i) an early innate type 1 interferon response and (ii) a neutralizing antibody response. The model is described by the following system of equations:
Target cells, T, are infected by free virus V with rate b when no antibody, A, is present, and become non-productively infected cells, I 1 . While cells are non-productively infected they are referred to as being in the eclipse phase, and they transition to productively infected cells I 2 at per capita rate k giving a mean eclipse phase of length 1/k. Productively infected cells die at per capita rate d and produce virus, in the absence of interferon F, at rate p per cell, which is then cleared at rate c per virion.
In vitro there is detectable virus in cell culture supernatants 6 hr after Zika infection of primary human fibroblasts (Hamel et al., 2015) . We fixed the value of k at 4 d -1 so that the mean eclipse phase length was 6 hr, since there is not enough information in the data to estimate it precisely. We also set the value of c to be 25 d -1 , similar to the value estimated for HIV-1 (Ramratnam et al., 1999) and HCV (Guedj et al., 2013) .
Productively infected cells cause the production of interferon at rate s after a lag of length t. As expression of ISGs was detected at day 2, we investigated values of t = 0.25, 0.5, 1, and 1.5 days. Without loss of generality we can set s = 1 d -1 , so that one productively infected cell creates one 'unit' of interferon per day. Interferon is cleared at constant rate g and reduces the production rate of virus particles from infected cells with a coefficient ε. In previous work fitting a similar model to data from influenza infected ponies (Pawelek et al., 2012) it was estimated that interferon is cleared at a rate of approximately 2 d -1 , as so we took this as the value of g. The model assumes neutralizing antibody, A, reduces the infection rate b by the factor (1+ aA(t)). We used linear interpolation between measured neutralization titers to estimate A(t), under the assumption that A(t) = 0 for all t below some value, denoted T ab . Because neutralizing antibody was detected at day 7, we investigated values of T ab = 3, 4, 5 or 6 days.
We set the initial conditions of this system such that there are no infected cells, interferon or neutralizing antibody at time t = 0 and as in previous work (Osuna et al., 2016) we fixed the initial target cell population density at T(0) = T 0 = 10 5 cells/ml.
In order to evaluate the effects of immunological control of ZIKV, we considered models where (a) there is no effect of neutralizing antibody or interferon (a = 0, ε = 0), (b) there is an effect of antibody but no effect of interferon (ε = 0) and (c) both neutralizing antibody and interferon affect the viral dynamics. For each of these models, we estimated the distribution of the non-fixed parameters and the initial condition V(0) = V 0 using a population fitting approach with a non-linear mixed effects model implemented in Monolix (http:// lixoft.com/products/monolix/), providing estimates of population medians and standard errors for each of the parameters. We assessed model fits by the negative log likelihood and the appropriateness of the various models of immune control using the Bayesian information criterion (BIC), both as provided by Monolix.
STATISTICAL ANALYSES
Analysis of virologic and immunologic data was performed using GraphPad Prism v6.03 (GraphPad Software, CA, USA). Comparisons of groups were performed using Student t test and Wilcoxon rank-sum test. Correlations of virologic and immunologic data were assessed by Spearman rank-correlation tests. A p value cut-off of 0.05 was considered statistically significant. Top: Heatmaps representing log 2 fold change of top genes correlated positively (red) and negatively (blue) to viral loads in CSF on days 14 and 21. Cell cycle, oxidative phosphorylation, interferon, and inflammatory signaling pathways are shown in the left box, and extracellular matrix, RAS signaling, cell adhesion and development, myeloid and leukocytes differentiation, platelets, and plasma membrane signaling pathways are shown in the right box. Red and blue color gradient represents, respectively, increased and decreased log 2 fold gene expression changes in animals with positive versus negative CSF viral loads. Middle: Heatmaps showing log 2 fold change of the top genes correlated positively (red) and negatively (blue) to viral loads in LN on day 3 and 14. mTOR, PI3K, NOTCH, interferon, NFAT, TCR, B cell, and antigen presentation and processing signaling pathways are shown in the left box, and neurotransmitter receptor, extracellular matrix, proteoglycans, FGFR signaling, and cell junction signaling pathways are shown in the right box. Red and blue color gradient represents, respectively, increased and decreased log 2 fold gene expression changes in animals with positive versus negative LN viral loads. Bottom: Heatmaps representing the log 2 fold change expression of pro-and anti-apoptotic genes between animals with positive versus negative viral loads in CSF (days 14 and 21) and LN (day 14). Red and blue color gradient represents, respectively, increased and decreased log 2 fold gene expression changes in animals with positive versus negative CSF and LN viral loads.
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